Bayer's High Hopes For Huntington's Gene Therapy As Novartis’s Branaplam Stumbles

France Gives Thumbs-Up To Trial

When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.

DNA
• Source: Alamy

The Huntington's disease research field is littered with failures but Bayer AG is hoping that a gene therapy developed at one of its subsidiaries will provide a significant advance in tackling the rare progressive neurodegenerative disorder.

Asklepios BioPharmaceutical, Inc. (AskBio), acquired by Bayer at the end of 2020 for $2bn upfront, has received clearance to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies